期刊文献+

斯普林治疗化疗所致骨髓抑制和改善生活质量的效果 被引量:10

The effect of sipulin in improving marrow depress and sympton induced by chemotherapy
暂未订购
导出
摘要 目的:观察斯普林对恶性肿瘤患者化疗的辅助疗效。方法:化疗前2个周期不加斯普林,后3个-6个周期加斯普林,10ml/日,静脉点滴,每周期连用10天,从化疗第1日开始。所有患者加斯普林前后方案、剂量完全相同。结果:22例化疗患者加斯普林治疗前后外周血象及临床毒副反应有明显变化,加斯普林前WBC、PCT、HB发生Ⅰ度-Ⅲ度反应分别为72.7%、45.5%、31.7%,加斯普林后发生Ⅰ度-Ⅲ度反应分别为45.4%、40.9%、22.7%。加斯普林前神疲乏力、食欲不振、腹胀/便秘发生率为100%,加斯普林后症状好转56.2%,消失43.8%,有效率100%。结论:斯普林具有升高外周血象、改善生活质量、提高患者对化疗耐受性的作用。 Objective: To observe the effect combined spulin with chemotherapy in the patients with malignant tumour. Methods:Twenty two advanced malighamt tumour patients tvedated with four or six cycles chemotherapy, every cycle was 21 days. After 1 and 2 cyles patients were given sipulin 10ml/d,lasted 10 days. Results: All patients who were given sipulin had obvious changes in blood routine and drug effects. Before use the sipulin, WBC, PCT, HB occur Ⅰ-Ⅲ actions,in 72.7% ,45.5% ,31.7% ,patients respectively, patients not given sipulin appeared frazzle, inappetence and constipation were 100% after chemotherapy. The effective rate of sipulin in the improving symptoms of patients was 100%. Conclusion: Sipulin can improve the blood routine, life quality and tolerance of the patients with chemotherapy.
出处 《现代肿瘤医学》 CAS 2007年第2期262-263,共2页 Journal of Modern Oncology
关键词 恶性肿瘤 化疗 骨髓抑制 生活质量 斯普林 tumour chemotherapy marrow depress life quality sipulin
  • 相关文献

参考文献4

二级参考文献14

  • 1徐国柱,蔡志基.镇痛药临床评价方法研究[J].中国新药杂志,1995,4(4):20-22. 被引量:256
  • 2黄挺 等.应用小剂量白细胞介素-2和干扰素综合治疗中、晚期癌症的观察[J].中国癌症杂志,1993,9(2):113-113.
  • 3Vadhan Raj S, Verschraegen C F, Bueso Ramos C, et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer[J]. Ann Intern Med, 2000,132(5) :364-368.
  • 4Kaushansky K. Use of thrombopoietic growth factors in acute leukemia[J]. Leukemia, 2000, 14(3):505-508.
  • 5Paul S R, Bennett F, Calvetti J A, et al. Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine[J]. Proc Natl Acad Sci U S A,1990, 87(19) :7512-7516.
  • 6Reynolds C H. Clinical efficacy of rhIL-11[J]. Oncology(Huntingt), 2000, 14(9 Suppl 8) :32-40.
  • 7Saitoh M, Taguchi K, Momose K, et al. Recombinant human interleukin-11 improved carboplatin-induced thrombocytopenia without affecting antitumor activities in mice bearing Lewis lung carcinoma cells [J]. Cancer Chemother Pharmacol, 2002, 49(2) :161-166.
  • 8Saitoh M, Taguchi K, Momose K, et al. Kinetic analysis of megakaryopoiesis induced by recombinant human interleukin 11in myelosuppressed mice[J]. Cytokine, 2001,13(5) :287-294.
  • 9Michael S. Gordon Thrombopoietic activity activity of recombinant human interleukin 11 in cancer patients receiving chemotherapy[J]. Cancer Chemother Pharmacol, 1996 (Suppl): 596-598.
  • 10罗健,李松,孙燕.生活质量与癌症疼痛:透皮芬太尼与口服吗啡的满意度和不良反应比较[J].中国新药杂志,1999,8(7):490-494. 被引量:17

共引文献43

同被引文献53

引证文献10

二级引证文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部